04-Cancer immunotherapy Cancer immunotherapy From Wikipedia,the free encyclopedia Cancer imm erapy (m-onor totrea cancer Immunoth passive or hybrid(active and passive).These approaches exploit the fact that cancer cells often have molecules on heir sur e that can be det Dy th often proteins or other macromolecules (e carbohydrates).Active immunotherapy directs the immune G system【o attack tu mor cells by targeting TAAs.Passive s en and cytokines. Among these rapies system that bind to a tar omemgmeotTeehodiesrtproeciipovCeSeoane n pathogens.Each antibody is specific to one or a few proteins.Those that bind to tumor antigens treat cancer rtace receptors are com non targets I antibo ody therapies and ir lude CD20,CD27 and CD279.Once Approved antibodies include alemtuzumab,iplimumab,nivolumab,ofatumumab and rituximab. Active cellular th ual of in mune cells from the blood or fro r.Thos immune cells can be genetically engineered to express a tumor-specific receptor,cultured and returned to the patient.Cell types t be use in this v cells,lymphokin e-activated killer cells -approved cell-based therapy is Dendren's Provenge for th Interleukin-and in a are cytokin regula e and coordinate the behaviour of the immune ed in the tre related Ka ci'c ma,follicular lymphoma,chronic myeloid leukaemia and malignant melanoma.Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma. Contents 3 Antibody therapy dy types 3.3 FDA-app .5 Combination immunotherapy .6 Combinatorial ablation and immunotherapy 04-Cancer immunotherapy